Meeting
2023 ASCO Annual Meeting
CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).
Authors
Michael D. Staehler
University of Munich, Muenchen, Germany
Michael D. Staehler , Pierre Bigot , Philippe Barthelemy , Paul Hamberg , Cristina Suárez , Jean-Christophe Eymard , Pablo Gajate , Valérie Perrot , Bryan Qvick , Pascale Dutailly , Giuseppe Procopio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03419572
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4529)
DOI
10.1200/JCO.2023.41.16_suppl.4529
Abstract #
4529
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.
First Author: Michael D. Staehler
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS).
First Author: Antoine Thiery-Vuillemin
Poster
2020 ASCO Virtual Scientific Program
A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.
First Author: Mototsugu Oya
Poster
2017 ASCO Annual Meeting
Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
First Author: Frede Donskov